Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18633532 | 0.98 | FFAR4 (0.39) | FFAR4ACACBACACAFFAR1TBXAS1 | |
| SCHEMBL186552 | 0.98 | FFAR4 (0.37) | FFAR4ACACBACACAFFAR1TBXAS1 | |
| SCHEMBL14106427 | 0.94 | TBXAS1 (0.41) | FFAR4ACACBACACAFFAR1TBXAS1 | |
| SCHEMBL186831 | 0.92 | TBXAS1 (0.46) | FFAR4ACACBACACAFFAR1TBXAS1 | |
| SCHEMBL17764132 | 0.92 | TBXAS1 (0.36) | FFAR4ACACBACACAFFAR1TBXAS1 | |
| SCHEMBL1151239 | 0.92 | CYP2C19 (0.34) | FFAR4ACACBACACAFFAR1TBXAS1 | |
| SCHEMBL17099445 | 0.91 | FFAR1 (0.54) | FFAR4FFAR1GPR84FAAHACE2 | |
| SCHEMBL1106809 | 0.91 | FFAR4 (0.39) | FFAR4ACACBACACAFFAR1TBXAS1 | |
| SCHEMBL187698 | 0.90 | TBXAS1 (0.40) | FFAR4ACACBACACAFFAR1TBXAS1 | |
| SCHEMBL186819 | 0.90 | CYP2C19 (0.44) | FFAR4ACACBACACAFFAR1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3119388-B1 | CARBOXY-CYCLOPROPYL UNDECANOL COMPOUNDS FOR TREATMENT OF LIVER DISEASE AND OTHER MEDICAL DISORDERS | ESPERION THERAPEUTICS INC (US) | 2020-06-17 | — | — | EP | claimed |
| US-20170209402-A1 | CARBOXY-CYCLOPROPYL UNDECANOL COMPOUNDS FOR TREATMENT OF LIVER DISEASE AND OTHER MEDICAL DISORDERS | ESPERION THERAPEUTICS, INC. | 2017-07-27 | — | — | US | claimed |
| EP-2402300-B1 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS INC (US) | 2016-05-25 | — | — | EP | claimed |
| CN-110054562-B | Substituted pentadecanedioic acid compound, pharmaceutical composition and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3119388-B1 | CARBOXY-CYCLOPROPYL UNDECANOL COMPOUNDS FOR TREATMENT OF LIVER DISEASE AND OTHER MEDICAL DISORDERS | ESPERION THERAPEUTICS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3119388-B1 | CARBOXY-CYCLOPROPYL UNDECANOL COMPOUNDS FOR TREATMENT OF LIVER DISEASE AND OTHER MEDICAL DISORDERS | ESPERION THERAPEUTICS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019179494-A1 | SUBSTITUTED PENTADECANEDIOIC ACID COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2019-09-26 | — | — | WO | disclosed |
| WO-2019179494-A1 | SUBSTITUTED PENTADECANEDIOIC ACID COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2019-09-26 | — | — | WO | disclosed |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | ESPERION THERAPEUTICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-7405226-B2 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PFIZER INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405226-B2 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PFIZER INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405226-B2 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PFIZER INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060229281-A1 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | ESPERION THERAPEUTIC, INC. | 2006-10-12 | — | — | US | disclosed |
| US-7119221-B2 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20040209847-A1 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | FFAR4 295/4885ACACB 204/4885ACACA 158/4885 |
| US-20170209402-A1 | CARBOXY-CYCLOPROPYL UNDECANOL COMPOUNDS FOR TREATMENT OF LIVER DISEASE AND OTHER MEDICAL DISORDERS | CES1, SLC10A1, LIPC | FFAR4 136/4885ACACB 35/4885ACACA 25/4885 |
| US-20040209847-A1 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | PNLIP, APOL1, NR1H3 | FFAR4 198/4885ACACB 238/4885ACACA 185/4885 |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | FFAR4 295/4885ACACB 204/4885ACACA 158/4885 |
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | PNLIP, NR1H3, NR1H2 | FFAR4 112/4885ACACB 78/4885ACACA 49/4885 |
| US-20060229281-A1 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PNLIP, CYP27A1, GPR119 | FFAR4 86/4885ACACB 315/4885ACACA 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.